Quinidine Kinetics After a Single Oral Dose in Relation to the Sparteine Oxidation Polymorphism in Man

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1990 Feb 1

PMID 2306418

Citations 11

Authors

K Brosen

F Davidsen

L F Gram

Affiliations

Soon will be listed here.

Abstract

The kinetics at a single oral dose (400 mg) of quinidine were studied in four extensive metabolizers (EM) and four poor metabolizers (PM) of sparteine. The clearance of quinidine by 3-hydroxylation was significantly lower in PM than in EM, but the difference was small (25-30%). This finding suggests that 3-hydroxylation, in part, is catalyzed by the same isoenzyme of cytochrome P450, P450db1 which oxidizes sparteine. Otherwise, no significant phenotypic differences in total or metabolic clearance were found and it is concluded that the metabolism of quinidine is largely carried out by P450 isoenzymes different from P450db1. A biexponential decline in the log plasma quinidine concentration vs time curves was observed in all subjects, and the mean elimination half-life was 11-12 h. This is about twice as long as generally reported in the literature.

Citing Articles

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Brown H, Ito K, Galetin A, Houston J Br J Clin Pharmacol. 2005; 60(5):508-18.

PMID: 16236041 PMC: 1884945. DOI: 10.1111/j.1365-2125.2005.02483.x.

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Kharasch E, Hoffer C, Whittington D Br J Clin Pharmacol. 2004; 57(5):600-10.

PMID: 15089813 PMC: 1884496. DOI: 10.1111/j.1365-2125.2003.02053.x.

Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Moghadamnia A, Rostami-Hodjegan A, Abdul-Manap R, Wright C, Morice A, Tucker G Br J Clin Pharmacol. 2003; 56(1):57-67.

PMID: 12848776 PMC: 1884341. DOI: 10.1046/j.1365-2125.2003.01853.x.

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Dalen P, Dahl M, Andersson K, Bertilsson L Br J Clin Pharmacol. 2000; 49(2):180-4.

PMID: 10671914 PMC: 2014903. DOI: 10.1046/j.1365-2125.2000.00120.x.

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

Nielsen F, Rosholm J, Brosen K Eur J Clin Pharmacol. 1995; 48(6):501-4.

PMID: 8582470 DOI: 10.1007/BF00194341.

References

Evans D, Mahgoub A, Sloan T, Idle J, Smith R . A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980; 17(2):102-5. PMC: 1048511. DOI: 10.1136/jmg.17.2.102. View

Ochs H, Greenblatt D, Woo E . Clinical pharmacokinetics of quinidine. Clin Pharmacokinet. 1980; 5(2):150-68. DOI: 10.2165/00003088-198005020-00003. View

Otton S, Inaba T, KALOW W . Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984; 34(1):73-80. DOI: 10.1016/0024-3205(84)90332-1. View

Rakhit A, Holford N, Guentert T, Maloney K, RIEGELMAN S . Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm. 1984; 12(1):1-21. DOI: 10.1007/BF01063608. View

Inaba T, Nakano M, Otton S, Mahon W, KALOW W . A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Can J Physiol Pharmacol. 1984; 62(7):860-2. DOI: 10.1139/y84-144. View

Vozeh S, Uematsu T, Guentert T, Ha H, Follath F . Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther. 1985; 37(5):575-81. DOI: 10.1038/clpt.1985.90. View

Brosen K, Otton S, Gram L . Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh). 1985; 57(5):357-60. DOI: 10.1111/j.1600-0773.1985.tb00058.x. View

Leemann T, Dayer P, Meyer U . Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986; 29(6):739-41. DOI: 10.1007/BF00615971. View

Guengerich F, Blair I . Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986; 30(3):287-95. View

10.

Brinn R, Brosen K, Gram L, Haghfelt T, Otton S . Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol. 1986; 22(2):194-7. PMC: 1401116. DOI: 10.1111/j.1365-2125.1986.tb05250.x. View

11.

Mikus G, Ha H, Vozeh S, Zekorn C, Follath F, Eichelbaum M . Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol. 1986; 31(1):69-72. DOI: 10.1007/BF00870989. View

12.

Speirs C, Murray S, Boobis A, Seddon C, Davies D . Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986; 22(6):739-43. PMC: 1401220. DOI: 10.1111/j.1365-2125.1986.tb02969.x. View

13.

Brosen K, Gram L, Haghfelt T, Bertilsson L . Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol. 1987; 60(4):312-4. DOI: 10.1111/j.1600-0773.1987.tb01758.x. View

14.

Gonzalez F, Skoda R, Kimura S, Umeno M, Zanger U, Nebert D . Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988; 331(6155):442-6. DOI: 10.1038/331442a0. View

15.

Otton S, Brinn R, Gram L . In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos. 1988; 16(1):15-7. View

16.

Zanger U, Vilbois F, Hardwick J, Meyer U . Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry. 1988; 27(15):5447-54. DOI: 10.1021/bi00415a010. View

17.

Brosen K, Gram L . Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989; 36(6):537-47. DOI: 10.1007/BF00637732. View

18.

Mahon W, Mayersohn M, Inaba T . Disposition kinetics of two oral forms of quinidine. Clin Pharmacol Ther. 1976; 19(5 Pt 1):566-75. DOI: 10.1002/cpt1976195part1566. View

19.

Ueda C, Williamson B, Dzindzio B . Absolute quinidine bioavailability. Clin Pharmacol Ther. 1976; 20(3):260-5. DOI: 10.1002/cpt1976203260. View

20.

Ueda C, Dzindzio B . Quinidine kinetics in congestive heart failure. Clin Pharmacol Ther. 1978; 23(2):158-64. DOI: 10.1002/cpt1978232158. View